BioPharma-Synergy (23rd -25th February 2021)
The event is designed for the BD&Licensing pharma professionals focusing on BioSimilars, BioBetter & BioInnovative products. With the audience coming from Europe, LATAM, APAC, MENA & North America – BioPharma-Synergy invites dynamic pharma companies for three days of business partnering meetings and content-driven programme.
Speaker faculty includes:
- Jean-Baptiste Duval, Head of International Operations, Shanghai Henlius Biotech
- Philippe Gautron, Senior Director, Global Business Development own brands, DKSH
- Eduardo Cioppi, Regional Director – Latin America, mAbxience
- Stephani Saverio, Senior Director, Business Development, Knight Therapeutics
- Xiaoli Hu, Head of Business Development, Xbrane Biopharma AB
- Pavan Handa, Executive Vice President and Chief Business Officer, Kashiv Pharm
- Thiago Mares Guia, Scientific & Business Executive Director, Bionovis
- Carlos Berrade, Licensing & Business Development Director, Kern Pharma
- Marco Cerato, Senior Vice President, Global Corporate and Business Development, Mundipharma
- Anil Okay, General Manager at Adalvo, Chief Commercial Officer, Alvotech
- Gopal Rao, Global Business Development, Biotech Division Lupin
- Radhika Bhalla, Head of Emerging Asia Alliance Markets, Viatris
- Bert Thomas, SVP Business Development, Bio-Thera Solutions
- Wen Ries-Shi, VP Europe General Manager, Techdow Pharma Shenzhen, Hepalink Pharmaceutical Group
- Debraj Dasgupta, VP, Global Head of Strategic Portfolio and Markets, Biocon Biologics
Discussions and presentations
The 2021 content-driven programme will focus on successful commercial strategies, pricing consideration, facilitating partnering across Geos between producers and buyers. Among the topics:
Global Biosimilars/Biobetter outlook; key players and their market access strategies
Regulatory approvals, tenders and pricing trends in Europe
Opportunities and trends in biosimilars by region: APAC, MENA, CIS, LATAM
Strategic considerations for biosimilar commercialisation – manufacturers’ point of view
In-licensing strategies in Europe and beyond